Format

Send to

Choose Destination
Gynecol Oncol. 2017 Feb;144(2):377-383. doi: 10.1016/j.ygyno.2016.11.045. Epub 2016 Dec 9.

Identification of novel mutations in Japanese ovarian clear cell carcinoma patients using optimized targeted NGS for clinical diagnosis.

Author information

1
Department of Molecular Carcinogenesis, Chiba Cancer Center Research Institute, Chiba, Japan; Department of Molecular Biology and Oncology, Graduate School of Medical and Pharmaceutical Sciences, Chiba University, Chiba, Japan.
2
Department of Gynecology, Chiba Cancer Center, Chiba, Japan.
3
Laboratory of Cancer Genomics, Chiba Cancer Center Research Institute, Chiba, Japan.
4
Division of Surgical Pathology, Chiba Cancer Center, Chiba, Japan.
5
Department of Molecular Carcinogenesis, Chiba Cancer Center Research Institute, Chiba, Japan.
6
Department of Molecular Biology and Oncology, Graduate School of Medical and Pharmaceutical Sciences, Chiba University, Chiba, Japan; Laboratory of Cancer Genetics, Chiba Cancer Center Research Institute, Chiba, Japan. Electronic address: hnagase@chiba-cc.jp.

Abstract

OBJECTIVE:

Ovarian clear cell carcinoma (OCCC) is an aggressive ovarian cancer with a higher frequency in Japan and often becomes chemorefractory disease. Reliable genetic diagnosis is essential to affirm the success of precision medicine for OCCC treatment. The aim of this study is, therefore, to identify novel mutations in OCCCs and develop a feasible clinical next generation sequencing (NGS) approach using formalin-fixed paraffin-embedded (FFPE) rather than preferable but not always available fresh frozen (FF) samples.

METHODS:

We optimized and evaluated exome analyses of 409 cancer-related genes using FFPE and FF DNA and analyzed NGS data to identify somatic mutations in Japanese OCCCs.

RESULTS:

Sufficient and good quality DNAs from FFPE samples were extracted from 18 (FIGO Stage I: 12) out of 29 pairs of matched normal and OCCC for NGS (63%). The fine quality of extracted DNAs depended on the length of storage period (<2years storage). We also identified 45 somatic mutations in 34 genes including unreported variants from those FFPE DNA, in which somatic mutations in the PIK3CA gene was the most common (28%) as previously reported. Seven genes (PIK3CA, ARID1A, CTNNB1, CSMD3, LPHN3, LRP1B, and TP53) were mutated in at least two independent OCCCs. FF samples from 3 out of those 18 OCCCs were available and 13 out of 14 FFPE somatic mutations were confirmed.

CONCLUSIONS:

We successfully identified novel genetic alterations in Japanese OCCCs and demonstrated a feasible clinical diagnostic procedure using targeted NGS for OCCC FFPE samples.

KEYWORDS:

Clinical sequencing; FFPE; Next-generation sequencing; Ovarian clear cell carcinoma; Somatic mutations

PMID:
27939411
DOI:
10.1016/j.ygyno.2016.11.045
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center